The global macular degeneration treatment market is estimated to grow at a CAGR of nearly 7.0% during the forecast period. Due to the increasing geriatric population and the rising incidences of age-related macular degeneration (AMD), the pharmaceutical companies are working towards reinforcing their pipeline products for AMD treatment. Several companies are focusing on the development of intravitreal and oral drugs for the treatment of AMD. The companies whose medications are under clinical phases for AMD treatment include Bausch Health Companies Inc., Alkahest, Inc., and IVERIC bio, Inc. Some of the products have gained fast track designation for their products owing to the lack of availability for such kinds of drugs for the treatment of the condition. The description of pipeline products comprises-
To Request a Sample of our Report on Global Macular Degeneration Treatment Market: https://www.omrglobal.com/request-sample/macular-degeneration-treatment-market
In April 2020, Clearside Biomedical, Inc. declared a revise to the XIPERE (triamcinolone acetonide suprachoroidal injectable suspension). The company has submitted a new drug application (NDA) resubmission timeline and partnership for commercialization and development of XIPERE with Bausch Health Companies Inc. Along with the update, Clearside and Bausch Health have modified and revised their collaboration for XIPERE. In October 2019, Bausch + Lomb acquired an exclusive license to commercialize and develop XIPERE in the US and Canada.
Now, Bausch + Lomb has been permitted exclusive rights to commercialize and develop XIPERE in Australia and New Zealand, South America and Mexico, and the UK and Europe. Bausch + Lomb has prolonged the duration permitted for Clearside to get approval for XIPERE in the US. In the fourth quarter of 2020, Clearside may resubmit the NDA for XIPERE. If XIPERE will be approved by the US FDA, it will be the first therapy available for patients with macular edema associated with uveitis
- In April 2020, IVERIC bio, Inc. declared the fast track designation by the US FDA for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, which is in development to treat geographic atrophy (GA) secondary to dry AMD. GA is the advanced stage of AMD, which results in further irreversible vision loss in patients. Currently, there is no approved treatment by the US FDA or European Medicines Agency (EMA) for patients suffering from GA secondary to dry AMD. The fast track designation may support to recognize the effectiveness of Zimura to fulfill the unmet medical requirements.
- In February 2020, Alkahest, Inc. declared the commencement of a phase IIb clinical trial of its AKST4290, an orally administered small molecule CCR3 inhibitor. The placebo-controlled dose-ranging trial of AKST4290-205 (PHTHALO) is intended to assess the effectiveness of AKST4290 to treat naïve neovascular AMD patients after three loading doses of anti-VEGF (aflibercept) therapy. If this oral drug will be considered safe and effective in trials, it will become a treatment alternative for neovascular AMD that would meet a significant unmet medical and patient need.
Such kinds of novel pipeline products are expected to increase the efficacy and reliability of AMD treatment, which in turn, will offer an opportunity for the global macular degeneration treatment market. More drugs are expected to be in clinical phases in the future owing to the increasing collaboration for the development of more targeted therapies for AMD treatment.
(Get 15% Discount on Buying this Report)
A full Report of Global Macular Degeneration Treatment Market is Available at: https://www.omrglobal.com/industry-reports/macular-degeneration-treatment-market
Global Macular Degeneration Treatment Market- Segmentation
By Type
- Dry Age-Related Macular Degeneration
- Wet Age-Related Macular Degeneration
By Route of Administration
- Intravitreal
- Intravenous
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of APAC
Rest of The World
- Latin America
- The Middle East and Africa
Company Profiles
- Alkahest, Inc.
- Allergan plc
- Amgen Inc.
- Bausch Health Companies Inc.
- Boehringer Ingelheim GmbH
- Clearside Biomedical, Inc.
- Exonate Ltd.
- F. Hoffman La-Roche AG
- Gemini Therapeutics, Inc.
- IVERIC bio, Inc.
- Mylan N.V.
- Neurotech Pharmaceuticals, Inc.
- Novartis International AG
- Ocular Therapeutix, Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- REGENXBIO Inc.
- Xcovery
Reasons for Buying from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/macular-degeneration-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
